 | • レポートコード：20QY06-04855 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、137ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、外陰膣カンジダ症薬のグローバル市場について種類別（ミコナゾール、クロトリマゾール、フルコナゾール、エコナゾール、その他）、用途別（病院＆クリニック、薬局）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・外陰膣カンジダ症薬市場の概要 ・世界の主要地域別外陰膣カンジダ症薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の外陰膣カンジダ症薬市場規模2015-2026：種類別（ミコナゾール、クロトリマゾール、フルコナゾール、エコナゾール、その他） ・世界の外陰膣カンジダ症薬市場規模2015-2026：用途別（病院＆クリニック、薬局） ・外陰膣カンジダ症薬の北米市場規模2015-2020 ・外陰膣カンジダ症薬のヨーロッパ市場規模2015-2020 ・外陰膣カンジダ症薬の中国市場規模2015-2020 ・外陰膣カンジダ症薬の日本市場規模2015-2020 ・外陰膣カンジダ症薬の東南アジア市場規模2015-2020 ・外陰膣カンジダ症薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Bayer、Perrigo、J & J、Pfizer、Bristol-Myers Squibb、Effik、Teva、Sanofi、Cisen Pharmaceutical、Kingyork Group） ・外陰膣カンジダ症薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・外陰膣カンジダ症薬の市場動向・機会・課題 ・調査の結論 |
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
Market Analysis and Insights: Global Drugs for Vulvovaginal Candidiasis Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Drugs for Vulvovaginal Candidiasis market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Drugs for Vulvovaginal Candidiasis industry.
Based on our recent survey, we have several different scenarios about the Drugs for Vulvovaginal Candidiasis YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 791.7 million in 2019. The market size of Drugs for Vulvovaginal Candidiasis will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
Global Drugs for Vulvovaginal Candidiasis Scope and Market Size
The global Drugs for Vulvovaginal Candidiasis market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Vulvovaginal Candidiasis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Drugs for Vulvovaginal Candidiasis market is segmented into
Miconazole
Clotrimazole
Fluconazole
Econazole
Other
Segment by Application, the Drugs for Vulvovaginal Candidiasis market is segmented into
Hospital & Clinic
Pharmacy
The Drugs for Vulvovaginal Candidiasis market is analysed and market size information is provided by regions (countries). Segment by Application, the Drugs for Vulvovaginal Candidiasis market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Drugs for Vulvovaginal Candidiasis Market Share Analysis
Drugs for Vulvovaginal Candidiasis market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Drugs for Vulvovaginal Candidiasis business, the date to enter into the Drugs for Vulvovaginal Candidiasis market, Drugs for Vulvovaginal Candidiasis product introduction, recent developments, etc.
The major vendors covered:
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
1 Drugs for Vulvovaginal Candidiasis Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Product Scope
1.2 Drugs for Vulvovaginal Candidiasis Segment by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2026)
1.2.2 Miconazole
1.2.3 Clotrimazole
1.2.4 Fluconazole
1.2.5 Econazole
1.2.6 Other
1.3 Drugs for Vulvovaginal Candidiasis Segment by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Comparison by Application (2020-2026)
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts (2015-2026)
1.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Growth Rate (2015-2026)
1.4.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2015-2026)
1.4.3 Global Drugs for Vulvovaginal Candidiasis Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Drugs for Vulvovaginal Candidiasis Industry Impact
1.5.1 How the Covid-19 is Affecting the Drugs for Vulvovaginal Candidiasis Industry
1.5.1.1 Drugs for Vulvovaginal Candidiasis Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Drugs for Vulvovaginal Candidiasis Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Drugs for Vulvovaginal Candidiasis Players to Combat Covid-19 Impact
2 Drugs for Vulvovaginal Candidiasis Estimate and Forecast by Region
2.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Drugs for Vulvovaginal Candidiasis Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2015-2020)
2.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2015-2020)
2.3 Global Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Drugs for Vulvovaginal Candidiasis Estimates and Projections (2015-2026)
2.4.2 Europe Drugs for Vulvovaginal Candidiasis Estimates and Projections (2015-2026)
2.4.3 China Drugs for Vulvovaginal Candidiasis Estimates and Projections (2015-2026)
2.4.4 Japan Drugs for Vulvovaginal Candidiasis Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Drugs for Vulvovaginal Candidiasis Estimates and Projections (2015-2026)
2.4.6 India Drugs for Vulvovaginal Candidiasis Estimates and Projections (2015-2026)
3 Global Drugs for Vulvovaginal Candidiasis Competition Landscape by Players
3.1 Global Top Drugs for Vulvovaginal Candidiasis Players by Sales (2015-2020)
3.2 Global Top Drugs for Vulvovaginal Candidiasis Players by Revenue (2015-2020)
3.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2019)
3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Company (2015-2020)
3.5 Manufacturers Drugs for Vulvovaginal Candidiasis Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Drugs for Vulvovaginal Candidiasis Players (Opinion Leaders)
4 Global Drugs for Vulvovaginal Candidiasis Market Size by Type
4.1 Global Drugs for Vulvovaginal Candidiasis Historic Market Review by Type (2015-2020)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2015-2020)
4.1.3 Global Drugs for Vulvovaginal Candidiasis Price by Type (2014-2020)
4.2 Global Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2021-2026)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2021-2026)
4.2.3 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Type (2021-2026)
5 Global Drugs for Vulvovaginal Candidiasis Market Size by Application
5.1 Global Drugs for Vulvovaginal Candidiasis Historic Market Review by Application (2015-2020)
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
5.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2015-2020)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Price by Application (2015-2020)
5.2 Global Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2021-2026)
5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2021-2026)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Application (2021-2026)
3 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures
3.2 North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
3.3 North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
3.4 North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
4 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures
4.2 Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
4.3 Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
4.4 Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
5 China Drugs for Vulvovaginal Candidiasis Market Facts & Figures
5.2 China Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
5.3 China Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
5.4 China Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
6 Japan Drugs for Vulvovaginal Candidiasis Market Facts & Figures
6.2 Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
6.3 Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
6.4 Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
7 Southeast Asia Drugs for Vulvovaginal Candidiasis Market Facts & Figures
7.2 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
8 India Drugs for Vulvovaginal Candidiasis Market Facts & Figures
8.2 India Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
8.3 India Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
8.4 India Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Drugs for Vulvovaginal Candidiasis Business
12.1 Bayer
12.1.1 Bayer Drugs for Vulvovaginal Candidiasis Corporation Information
12.1.2 Bayer Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bayer Drugs for Vulvovaginal Candidiasis Products Offered
12.1.5 Bayer Recent Development
12.2 Perrigo
12.2.1 Perrigo Drugs for Vulvovaginal Candidiasis Corporation Information
12.2.2 Perrigo Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Products Offered
12.2.5 Perrigo Recent Development
12.3 J & J
12.3.1 J & J Drugs for Vulvovaginal Candidiasis Corporation Information
12.3.2 J & J Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.3.4 J & J Drugs for Vulvovaginal Candidiasis Products Offered
12.3.5 J & J Recent Development
12.4 Pfizer
12.4.1 Pfizer Drugs for Vulvovaginal Candidiasis Corporation Information
12.4.2 Pfizer Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Products Offered
12.4.5 Pfizer Recent Development
12.5 Bristol-Myers Squibb
12.5.1 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Corporation Information
12.5.2 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Products Offered
12.5.5 Bristol-Myers Squibb Recent Development
12.6 Effik
12.6.1 Effik Drugs for Vulvovaginal Candidiasis Corporation Information
12.6.2 Effik Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Effik Drugs for Vulvovaginal Candidiasis Products Offered
12.6.5 Effik Recent Development
12.7 Teva
12.7.1 Teva Drugs for Vulvovaginal Candidiasis Corporation Information
12.7.2 Teva Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Teva Drugs for Vulvovaginal Candidiasis Products Offered
12.7.5 Teva Recent Development
12.8 Sanofi
12.8.1 Sanofi Drugs for Vulvovaginal Candidiasis Corporation Information
12.8.2 Sanofi Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Products Offered
12.8.5 Sanofi Recent Development
12.9 Cisen Pharmaceutical
12.9.1 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Corporation Information
12.9.2 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Products Offered
12.9.5 Cisen Pharmaceutical Recent Development
12.10 Kingyork Group
12.10.1 Kingyork Group Drugs for Vulvovaginal Candidiasis Corporation Information
12.10.2 Kingyork Group Drugs for Vulvovaginal Candidiasis Business Overview and Total Revenue
12.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Products Offered
12.10.5 Kingyork Group Recent Development
13 Drugs for Vulvovaginal Candidiasis Manufacturing Cost Analysis
13.1 Drugs for Vulvovaginal Candidiasis Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
13.4 Drugs for Vulvovaginal Candidiasis Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Drugs for Vulvovaginal Candidiasis Distributors List
14.3 Drugs for Vulvovaginal Candidiasis Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Growth Rate by Type (2020-2026)
Table 2. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Drugs for Vulvovaginal Candidiasis Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Drugs for Vulvovaginal Candidiasis Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Drugs for Vulvovaginal Candidiasis Players to Combat Covid-19 Impact
Table 8. Global Market Drugs for Vulvovaginal Candidiasis Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Region (2015-2020)
Table 10. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2015-2020)
Table 11. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Region (2015-2020)
Table 13. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Forecast by Region (2021-2026)
Table 14. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Drugs for Vulvovaginal Candidiasis Revenue Share Forecast by Region (2021-2026)
Table 17. Global Drugs for Vulvovaginal Candidiasis (K Units) of Key Companies (2015-2020)
Table 18. Global Drugs for Vulvovaginal Candidiasis Sales Share by Company (2015-2020)
Table 19. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Company (2015-2020)
Table 21. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2019)
Table 22. Global Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) of Key Company (2015-2020)
Table 23. Manufacturers Drugs for Vulvovaginal Candidiasis Manufacturing Sites and Area Served
Table 24. Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Drugs for Vulvovaginal Candidiasis Players
Table 27. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2015-2020)
Table 28. Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2015-2020)
Table 29. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Drugs for Vulvovaginal Candidiasis Price (K Units) by Type (2015-2020)
Table 31. Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2021-2026)
Table 32. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2021-2026)
Table 34. Global Drugs for Vulvovaginal Candidiasis Price (K Units) by Type (2021-2026)
Table 35. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2015-2020)
Table 36. Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2015-2020)
Table 37. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Drugs for Vulvovaginal Candidiasis Price (K Units) by Application (2015-2020)
Table 39. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2021-2026)
Table 40. Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2021-2026)
Table 41. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2021-2026)
Table 43. Global Drugs for Vulvovaginal Candidiasis Price (K Units) by Application (2021-2026)
Table 44. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2015-2020)
Table 45. United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
Table 46. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2015-2020)
Table 47. United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
Table 48. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2015-2020)
Table 49. United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
Table 50. Europe Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2015-2020)
Table 51. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
Table 52. Europe Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2015-2020)
Table 53. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
Table 54. Europe Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2015-2020)
Table 55. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
Table 56. China Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2015-2020)
Table 57. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
Table 58. China Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2015-2020)
Table 59. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
Table 60. China Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2015-2020)
Table 61. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
Table 62. Japan Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2015-2020)
Table 63. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
Table 64. Japan Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2015-2020)
Table 65. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
Table 66. Japan Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2015-2020)
Table 67. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2015-2020)
Table 69. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2015-2020)
Table 71. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2015-2020)
Table 73. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
Table 74. India Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2015-2020)
Table 75. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2015-2020)
Table 76. India Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2015-2020)
Table 77. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2015-2020)
Table 78. India Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2015-2020)
Table 79. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2015-2020)
Table 80. Bayer Corporation Information
Table 81. Bayer Description and Business Overview
Table 82. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 84. Bayer Recent Development
Table 85. Perrigo Corporation Information
Table 86. Perrigo Description and Business Overview
Table 87. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Perrigo Drugs for Vulvovaginal Candidiasis Product
Table 89. Perrigo Recent Development
Table 90. J & J Corporation Information
Table 91. J & J Description and Business Overview
Table 92. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. J & J Drugs for Vulvovaginal Candidiasis Product
Table 94. J & J Recent Development
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Business Overview
Table 97. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Pfizer Drugs for Vulvovaginal Candidiasis Product
Table 99. Pfizer Recent Development
Table 100. Bristol-Myers Squibb Corporation Information
Table 101. Bristol-Myers Squibb Description and Business Overview
Table 102. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table 104. Bristol-Myers Squibb Recent Development
Table 105. Effik Corporation Information
Table 106. Effik Description and Business Overview
Table 107. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Effik Drugs for Vulvovaginal Candidiasis Product
Table 109. Effik Recent Development
Table 110. Teva Corporation Information
Table 111. Teva Description and Business Overview
Table 112. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Teva Drugs for Vulvovaginal Candidiasis Product
Table 114. Teva Recent Development
Table 115. Sanofi Corporation Information
Table 116. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Sanofi Description and Business Overview
Table 118. Sanofi Drugs for Vulvovaginal Candidiasis Product
Table 119. Sanofi Recent Development
Table 120. Cisen Pharmaceutical Corporation Information
Table 121. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 122. Cisen Pharmaceutical Description and Business Overview
Table 123. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table 124. Cisen Pharmaceutical Recent Development
Table . Kingyork Group Corporation Information
Table . Kingyork Group Description and Business Overview
Table . Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table . Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table . Kingyork Group Recent Development
Table 130. Production Base and Market Concentration Rate of Raw Material
Table 131. Key Suppliers of Raw Materials
Table 132. Drugs for Vulvovaginal Candidiasis Distributors List
Table 133. Drugs for Vulvovaginal Candidiasis Customers List
Table 134. Market Key Trends
Table 135. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 136. Key Challenges
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Drugs for Vulvovaginal Candidiasis Market Share by Application in 2020 & 2026
Figure 6. Hospital & Clinic Examples
Figure 7. Pharmacy Examples
Figure 8. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Growth Rate (2015-2026)
Figure 9. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Growth Rate (2015-2026)
Figure 10. Global Drugs for Vulvovaginal Candidiasis Price Trends Growth Rate (2015-2026) (USD/Unit)
Figure 11. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region: 2015 VS 2020
Figure 12. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region: 2021 VS 2026
Figure 13. United States Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2015-2026)
Figure 14. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) Growth Rate (2015-2026)
Figure 15. Europe Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. Europe Drugs for Vulvovaginal Candidiasis Sales (Million USD) Growth Rate (2015-2026)
Figure 17. China Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. China Drugs for Vulvovaginal Candidiasis Sales (Million USD) and Growth Rate (2015-2026)
Figure 19. Japan Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. Japan Drugs for Vulvovaginal Candidiasis Sales (Million USD) Growth Rate (2015-2026)
Figure 21. Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales (Million USD) Growth Rate (2015-2026)
Figure 23. India Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. India Drugs for Vulvovaginal Candidiasis Sales (Million USD) Growth Rate (2015-2026)
Figure 25. Global 5 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue in Drugs for Vulvovaginal Candidiasis 2015 & 2019
Figure 26. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 27. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2015-2020)
Figure 28. Global Drugs for Vulvovaginal Candidiasis Revenue Growth Rate by Type in 2015 & 2019
Figure 29. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2015-2020)
Figure 30. Global Drugs for Vulvovaginal Candidiasis Revenue Growth Rate by Application in 2015 & 2019
Figure 31. United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2019
Figure 32. United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2019
Figure 33. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Company in 2019
Figure 34. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2019
Figure 35. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2019
Figure 36. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Company in 2019
Figure 37. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2019
Figure 38. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2019
Figure 39. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Company in 2019
Figure 40. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2019
Figure 41. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2019
Figure 42. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Company in 2019
Figure 43. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2019
Figure 44. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2019
Figure 45. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Company in 2019
Figure 46. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2019
Figure 47. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2019
Figure 48. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Perrigo Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. J & J Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Effik Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Cisen Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Kingyork Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Key Raw Materials Price Trend
Figure 59. Manufacturing Cost Structure of Drugs for Vulvovaginal Candidiasis
Figure 60. Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
Figure 61. Drugs for Vulvovaginal Candidiasis Industrial Chain Analysis
Figure 62. Channels of Distribution
Figure 63. Distributors Profiles
Figure 64. Porter's Five Forces Analysis
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
エクセナチド薬の世界市場レポート2020 A recently published report by QY Research titled Global Exenatide Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate da…- リラグルチド薬の世界市場レポート2020 A recently published report by QY Research titled Global Liraglutide Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate …
- コリン作動薬の世界市場レポート2020 Market Analysis and Insights: Global Cholinergic Drugs Market The global Cholinergic Drugs market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Cholinergic Drugs Scope and Market Size The global Cholinergic Dr…
- グラチラマー薬の世界市場レポート2020 A recently published report by QY Research titled Global Glatiramer Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate d…
- 内分泌系薬の世界市場レポート2020 Market Analysis and Insights: Global Endocrine System Drugs Market The global Endocrine System Drugs market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Endocrine System Drugs Scope and Market Size The global…